A Phase 1b/2 Open-Label Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer

Brief description of study

The purpose of the study is to determine the safety and efficacy of the treatments: AB928, a novel adenosine receptor blocker, plus zimberelimab, an anti-PD1 antibody, alone or in combination with a standard of care (enzalutamide, docetaxel) or AB928 plus AB680, a novel CD73 inhibitor, with or without zimberelimab. The investigational drugs are AB928, zimberelimab, and AB680. These drugs have not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States.

Clinical Study Identifier: s19-01947
ClinicalTrials.gov Identifier: NCT04381832

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.